#Oligonucleotide Synthesis Market size
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
The total number of visits Tumblr.com received during January 2021 is 327 million.
Text
Revenue Forecast and Competitive Landscape for the Oligonucleotide Synthesis Market
The Oligonucleotide Synthesis Market Report for 2024 provides a comprehensive overview of the Oligonucleotide Synthesis Market industry, presenting crucial data and insights into market dynamics, including growth drivers, challenges, and future potential. The report evaluates the Oligonucleotide Synthesis Market Components, focusing on significant opportunities and trends that could shape the industry's trajectory.
According to Straits Research, the global Oligonucleotide Synthesis Market market size was valued at USD 7.74 billion in 2023. It is projected to reach from USD 8.84 billion in 2024 to USD 25.57 billion by 2032, growing at a CAGR of 14.2% during the forecast period (2024–2032).
Get a Sample PDF/Excel of report starting from USD 995 :https://straitsresearch.com/report/oligonucleotide-synthesis-market/request-sample
Top Key Players of Oligonucleotide Synthesis Market :
Agilent Technologies, Inc.
ATDBio Ltd.
TriLink BioTechnologies LLC
Thermo Fisher Scientific
Nitto Denko Corporation
Merck KGaA
LGC Biosearch Technologies
Integrated DNA Technologies, Inc.
GenScript
GE Healthcare
Eurogentec
Eurofins
and more....
Key Insights from the Oligonucleotide Synthesis Market Report
Market Size Overview: The report provides comprehensive estimates of the Oligonucleotide Synthesis Marketsize, including value and sales volume, for the period.
Market Trends and Dynamics: An analysis of the key drivers, opportunities, challenges, and risks shaping the Oligonucleotide Synthesis Market.
Global Economic and Regional Impact: Evaluation of the effects of global inflation and the Russia-Ukraine conflict on the Oligonucleotide Synthesis Market.
Trade Flow Analysis: Detailed examination of import and export volumes of Oligonucleotide Synthesis Marketacross major regions.
Industry Value Chain: Insight into the Oligonucleotide Synthesis Marketvalue chain, covering raw materials, suppliers, manufacturing processes, distributors, and downstream customers.
Industry News, Policies, and Regulations: Coverage of the latest developments, policies, and regulations impacting the Oligonucleotide Synthesis Market.
Regional Analysis for Oligonucleotide Synthesis Market:
The regional analysis section of the report offers a thorough examination of the global Oligonucleotide Synthesis Market market, detailing the sales growth of various regional and country-level markets. It includes precise volume analysis by country and market size analysis by region for both past and future periods. The report provides an in-depth evaluation of the growth trends and other factors impacting the Oligonucleotide Synthesis Market market in key countries, such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil, and Saudi Arabia. Moreover, it explores the progress of significant regional markets, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
Oligonucleotide Synthesis Market Segmentations:
By Product Type
Synthesized Oligonucleotide Product
Reagents
Equipment
By Applications
Research
PCR
Sequencing
Gene Synthesis
Diagnostics
Therapeutics
RNAi
Nucleic Acid Aptamers
Others
By End-User
Academic Research Institutes
Pharmaceutical and Biotechnology Companies
Diagnostic Laboratories
Others
Get Detail Market Segmentation :https://straitsresearch.com/report/oligonucleotide-synthesis-market/segmentation
Unit Economics must be known by C-suite professionals:
Cost of Goods Sold (COGS): Includes material, labor, and overhead costs in manufacturing.
R&D Costs: Investment in innovation and compliance with regulations.
Engineering and Design Costs: Resources for design, prototyping, and meeting technical standards.
Production Costs: Specialized manufacturing and quality control expenses.
Supply Chain Costs: Managing procurement and logistics for specialized components.
Testing and Quality Assurance: Costs for ensuring product safety and reliability.
SG&A Costs: Marketing, sales, and administrative expenses.
Revenue per Unit: Income from contracts, services, and licensing.
Gross Margin: Revenue minus COGS, showing unit profitability.
Break-even Analysis: Units or contracts needed to cover total costs.
Customer Acquisition Cost (CAC): Costs to secure new contracts.
Lifetime Value (LTV): Total revenue from a customer over time.
Capital Expenditure (CapEx): Investments in facilities and technology.
Economies of Scale: Cost reductions in larger production runs.
Profit Margin: Final profit after all expenses.
Top Reasons to Choose This Report
Access to Comprehensive Insights: Gain access to extensive analysis, research, and data that are often challenging to gather independently. This report provides valuable information, saving you significant time and effort.
Support for Informed Decisions: Enhance your decision-making process with in-depth insights into market trends, consumer behavior, and key industry factors. This report is essential for strategic planning, including investments, product development, and marketing strategies.
Gain a Competitive Edge: Stay competitive by understanding market dynamics and competitor strategies. The report provides detailed insights into competitor performance and market trends, helping you craft effective business strategies.
Cost-Effective Research Solution: Save on research costs by investing in this report, which offers a detailed and comprehensive analysis of the market. This cost-effective option eliminates the need for extensive independent research.
COVID-19 Aftermath and Geopolitical Influences: Russia-Ukraine Conflict and Middle East Crisis
The report explores the multifaceted impact of COVID-19 on the Oligonucleotide Synthesis Market market, covering both direct and indirect effects across global and local levels. It discusses market size, trends, and growth trajectories in the Oligonucleotide Synthesis Market , classified by type, application, and customer sector. Additionally, it provides a detailed evaluation of market development components before and after the pandemic, supported by a PESTEL analysis to assess key influencers and barriers to market entry. We offer the flexibility to customize the report based on specific regions, applications, or any other statistical details. Our goal is to align our analysis with your specific needs, ensuring a more complete market study. The final report will also examine the impact of the Russia-Ukraine War on the Oligonucleotide Synthesis Market market, assessing how these geopolitical events are influencing current market conditions and future opportunities.
This Report is available for purchase on :https://straitsresearch.com/buy-now/oligonucleotide-synthesis-market
About Us:
Straits Research is a leading research and intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & research reports.
Contact Us: email: [email protected] Address: 825 3rd Avenue, New York, NY, USA, 10022 Tel: +1 646 905 0080 (U.S.) +91 8087085354 (India) +44 203 695 0070 (U.K.)
#Oligonucleotide Synthesis Market#Oligonucleotide Synthesis Market Share#Oligonucleotide Synthesis Market Size#Oligonucleotide Synthesis Market Research#Oligonucleotide Synthesis Industry#What is Oligonucleotide Synthesis?
0 notes
Text
Oligonucleotide Synthesis Market Analysis And Segment Forecast 2024-2030
The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030.
The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.
Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market
Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.
The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.
The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.
Oligonucleotide Synthesis Market Segmentation
Grand View Research has segmented the global oligonucleotide synthesis market report based on product & service, application, and region:
Product & Service Outlook (Revenue, USD Million, 2018 - 2030)
• Oligonucleotides
o DNA
o Column-based
o Array-based
o RNA
o By Technology
o Column-based
o Array-based
o By Type
o Short RNA Oligos (<65 nt)
o Long RNA Oligos (>65 nt)
o CRISPR (sgRNA)
• Equipment/Synthesizer
• Reagents
• Services
o DNA
o Custom Oligo Synthesis Services
o 25 nmol
o 50 nmol
o 200 nmol
o 1000 nmol
o 10000 nmol
o Modification Services
o Purification Services
o RNA
o Custom Oligo Synthesis Services
o 25 nmol
o 100 nmol
o 1000 nmol
o 10000 nmol
o Modification Services
o Purification Services
Application Outlook (Revenue, USD Million, 2018 - 2030)
• PCR Primers
o Academic Research Institutes
o Diagnostic Laboratories
o Pharmaceutical - Biotechnology Companies
• PCR Assays & Panels
o Academic Research Institutes
o Diagnostic Laboratories
o Pharmaceutical - Biotechnology Companies
• Sequencing
o Academic Research Institutes
o Diagnostic Laboratories
o Pharmaceutical - Biotechnology Companies
• DNA Microarrays
o Academic Research Institutes
o Diagnostic Laboratories
o Pharmaceutical - Biotechnology Companies
• Fluorescence In Situ Hybridization (FISH)
o Academic Research Institutes
o Diagnostic Laboratories
o Pharmaceutical - Biotechnology Companies
• Antisense Oligonucleotides
o Academic Research Institutes
o Diagnostic Laboratories
o Pharmaceutical - Biotechnology Companies
• Other Applications
Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait
Browse through Grand View Research's Biotechnology Industry Research Reports.
• The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030.
• The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030.
Key Companies & Market Share Insights
Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.
Key Oligonucleotide Synthesis Companies:
• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Danaher Corporation
• Dharmacon Inc.
• Agilent Technologies
• Bio-synthesis
• Kaneka Eurogentec S.A
• LGC Biosearch Technologies
• Biolegio
• Twist Bioscience
Recent Developments
• In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.
• In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.
• In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.
• In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.
• In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.
• In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.
Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.
#Oligonucleotide Synthesis Market#Oligonucleotide Synthesis Industry#Oligonucleotide Synthesis Market size#Oligonucleotide Synthesis Market share#Oligonucleotide Synthesis Market analysis
0 notes
Text
Oligonucleotide Synthesis Market is Expected to Witness High Growth Owing to Rising Biotechnology Research and Development
The oligonucleotide synthesis market involves the production of shorter sequences of nucleic acids known as oligonucleotides that are widely used in research, diagnostics and therapeutics applications. Oligonucleotides play a vital role in gene expression studies, next-generation sequencing, DNA & RNA analysis, qPCR and molecular diagnostics. The increasing focus on biotechnology research especially in life sciences and genomics has boosted the demand for specialized oligonucleotides.
The Global oligonucleotide synthesis market is estimated to be valued at US$ 4565 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period of 2024 to 2031.
Key Takeaways Key players operating in the oligonucleotide synthesis are Forte Research Systems (India), ICON plc (Ireland), Merge healthcare incorporated (U.S.), Bio-Optronics (U.S.), DSG INC (U.S.), ArisGlobal (India), ERT Clinical Bioclinica (U.S.), Oracle Corporation (U.S.), Medidata Solutions (U.S.), DATATRAK International, Inc. (U.S.), and MedNet Solutions, Inc., (U.S.) among others. These key players are focusing on partnerships and new technology development to expand their oligonucleotide synthesis capabilities.
Key Oligonucleotide Synthesis Market Demand include increasing research in personalized medicine and precision genomics. Additionally, the growing pipeline of oligo-based drugs and clinical trials for rare diseases will provide momentum.
With regards to geographical expansion, North America dominates the global oligonucleotide synthesis market followed by Europe. However, Asia Pacific is expected to witness highest growth rate owing to increasing government support for biotech sector and growing industry investments in China and India.
Market Drivers Increasing R&D expenditure for biotechnology research especially in life sciences and biopharmaceutical industry is a key factor contributing to the Oligonucleotide Synthesis Market Size And Trends Oligonucleotides play a vital role in new drug discovery and development which is propelling many biotech companies to adopt oligo synthesis. Rising applications of oligos in development of advanced therapeutics like antisense oligonucleotides and siRNA is expected to drive the market during the forecast period.
PEST Analysis Political: Government regulations around drug research and development have an impact. Changes in healthcare policies and funding also affect the market. Economic: The state of the economy influences research spending by pharmaceutical companies and academic institutions, affecting demand. Rising healthcare costs drive need for new drug therapies. Social: An aging global population with increased prevalence of diseases like cancer is leading to higher demand for advanced drug development and diagnostic tools. Social attitudes around health and biotech also evolve over time.
Technological: Advancements in DNA sequencing, synthesis and analysis technologies enable new applications and drive down costs, expanding the potential market. Automation and artificial intelligence are enhancing R&D productivity.
North America holds the largest share in terms of value currently due to heavy spending on drug R&D by major players in the US and Canada. However, Asia Pacific is expected to grow at the fastest rate during the forecast period as the pharmaceutical industry expands rapidly in major emerging economies like China and India. These countries are making large investments in research and increasing regulatory approvals are also supporting market growth.
Europe accounts for a sizable share as well owing to extensive government funding for research programs. However, the high costs of oligonucleotide therapies has limited their use thus far. If pricing and reimbursement improve in the future, the European market could witness stronger growth. On the other hand, the Middle East and Africa region is relatively nascent but demand may rise over time with economic development across various nations. Get More Insights On, Oligonucleotide Synthesis Market About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, c
#Oligonucleotide Synthesis Market Size#Oligonucleotide Synthesis Market Trends#Oligonucleotide Synthesis Market Analysis#Oligonucleotide Synthesis#Oligonucleotide Synthesis Market
0 notes
Text
Oligonucleotide Synthesis Market Size, Analysis and Forecast 2031
#Oligonucleotide Synthesis Market#Oligonucleotide Synthesis Market Scope#Oligonucleotide Synthesis Market Size#Oligonucleotide Synthesis Market Report
0 notes
Text
https://www.maximizemarketresearch.com/market-report/global-oligonucleotide-synthesis-market/31248/
Oligonucleotide Synthesis Market- Global Industry Analysis and Forecast (2023-2029)
Oligonucleotide Synthesis Market was valued at US$ 5.75 Bn in 2022 and is expected to reach 15.20Bn by 2029, at a CAGR of 14.87% during the forecast period.
#Oligonucleotide Synthesis Market size#Oligonucleotide Synthesis Market analysis#Oligonucleotide Synthesis Market share#Oligonucleotide Synthesis Market overview
0 notes
Text
#Oligonucleotide Synthesis Market#Oligonucleotide Synthesis Market size#Oligonucleotide Synthesis Market share#Oligonucleotide Synthesis Market trends#Oligonucleotide Synthesis Market analysis#Oligonucleotide Synthesis Market forecast#Oligonucleotide Synthesis Market outlook
0 notes
Text
According to Nova One Advisor, the U.S. oligonucleotide synthesis market size was valued at USD 1.55 billion in 2023 and is anticipated to reach around USD 5.22 billion by 2033, growing at a CAGR of 12.90% from 2024 to 2033.
0 notes
Text
The increasing prevalence of various chronic diseases in the United States like cancer represents one of the primary factors stimulating the market growth. Oligonucleotides are widely used in the development of advanced diagnostic tools, such as liquid biopsy tests and molecular diagnostics for infectious diseases. Additionally, the growing trend of personalized medicine is catalyzing the demand for oligonucleotides for diagnostics and therapies, propelling the market growth.
#United States Oligonucleotide Synthesis Market#United States Oligonucleotide Synthesis Market size#United States Oligonucleotide Synthesis Market share#United States Oligonucleotide Synthesis Market growth#United States Oligonucleotide Synthesis Market trends#United States Oligonucleotide Synthesis Market forecast#United States Oligonucleotide Synthesis Market 2024#United States Oligonucleotide Synthesis Market 2032
0 notes
Text
Global Oligonucleotide Synthesis Market Market Size, Share, Trends, Demand, Growth and Competitive Analysis
Oligonucleotide Synthesis Market research report has been prepared with the systematic gathering and evaluation of market information for industry which is presented in a form that explains various facts and figures to the business. Report saves valuable time as well as adds credibility to the work that is performed to grow business. This quality report has been planned with full commitment and transparency in research and analysis. With the systematic insights of this report, companies can self-assuredly take decisions about the production and marketing strategies. Oligonucleotide Synthesis Market document provides the same by studying the market and the industry with respect to numerous aspects.
Oligonucleotide Synthesis Market report gives explanation about the different segments of the market analysis which is demanded by today’s businesses. Key players are taking actions such as developments, product launches, acquisitions, mergers, joint ventures and competitive analysis in the industry. All the market aspects are estimated and analysed by a team of innovative, enthusiastic and motivated researchers and analysts so that nothing lefts uncovered in the report. Global Oligonucleotide Synthesis Market research report, it becomes easy to figure out brand awareness and insight about the brand and product among potential customers.
Oligonucleotide Synthesis Market, By Product (Oligonucleotide, Reagents, and Equipment), Type (Custom Oligos and Predesigned Oligos), Application (Therapeutic Applications, Diagnostics, Research, and Others), End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories and others) - Industry Trends and Forecast to 2030.
Access Full 350 Pages PDF Report @
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios of the top players in the Oligonucleotide Synthesis Market.
Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.
Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.
Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Oligonucleotide Synthesis Market.
Global Oligonucleotide Synthesis Market survey report analyses the general market conditions such as product price, profit, capacity, production, supply, demand, and market growth rate which supports businesses on deciding upon several strategies. Furthermore, big sample sizes have been utilized for the data collection in this business report which suits the necessities of small, medium as well as large size of businesses. The report explains the moves of top market players and brands that range from developments, products launches, acquisitions, mergers, joint ventures, trending innovation and business policies.
The following are the regions covered in this report.
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
The Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]
This study answers to the below key questions:
What are the key factors driving the Oligonucleotide Synthesis Market?
What are the challenges to market growth?
Who are the key players in the Oligonucleotide Synthesis Market?
What are the market opportunities and threats faced by the key players?
Some of the major players operating in the global oligonucleotide synthesis market are:
Agilent Technologies, Inc. (U.S.)
Atdbio Ltd.(U.K.)
LGC Limited (U.K.)
Bio-Synthesis Inc.(U.S.)
Eurofins Genomics (India),
Kaneka Eurogentec S.A.(Belgium)
General Electric (U.S.)
Genscript (U.S.)
AJINOMOTO CO.,INC (Genedesign, Inc.) (Tokyo)
Danaher (U.S.)
Merck Kgaa (Germany)
Browse Trending Reports:
Telehealth Market Size, Share, Trends, Growth Opportunities and Competitive Outlook https://www.databridgemarketresearch.com/reports/global-telehealth-market
Digital Health Technologies Market Size, Share, Trends, Demand, Growth, Challenges and Competitive Outlook https://www.databridgemarketresearch.com/reports/global-digital-health-technologies-market
Active Pharmaceutical Ingredient Api Market Size, Share, Key Drivers, Trends, Challenges and Competitive Analysis https://www.databridgemarketresearch.com/reports/global-active-pharmaceutical-ingredient-api-market
Clinical Oncology Next Generation Sequencing Market Size, Share, Demand, Future Growth, Challenges and Competitive Analysis https://www.databridgemarketresearch.com/reports/global-clinical-oncology-next-generation-sequencing-market
Generic Drug Market Size, Share, Trends, Growth Opportunities and Competitive Outlook https://www.databridgemarketresearch.com/reports/global-generic-drug-market
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: [email protected]
#Global Oligonucleotide Synthesis Market Market Size#Share#Trends#Demand#Growth and Competitive Analysis#market report#market size#market share#marketresearch#market trends#market analysis#markettrends#market research
0 notes
Text
Global Peptide And Oligonucleotide CDMO Market Analysis 2024: Size Forecast and Growth Prospects
The peptide and oligonucleotide cdmo global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Peptide And Oligonucleotide CDMO Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size - The peptide and oligonucleotide CDMO market size has grown rapidly in recent years. It will grow from $1.93 billion in 2023 to $2.16 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to a rise in demand for therapeutic agents, advancements in synthesis and manufacturing, personalized medicine trends, regulatory guidelines, and increased focus on antiviral peptides and mRNA vaccines highlighting the potential of oligonucleotides in vaccine development.
The peptide and oligonucleotide CDMO market size is expected to see rapid growth in the next few years. It will grow to $3.39 billion in 2028 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to the growing demand for personalized medicine, advancements in biotechnology, expanding applications, increasing outsourcing, and the growing burden of chronic diseases. Major trends in the forecast period include personalized therapies, technological advancements, quality control challenges, global expansion, and increased collaboration among biopharmaceutical companies.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report
Scope Of Peptide And Oligonucleotide CDMO MarketThe Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Peptide And Oligonucleotide CDMO Market Overview
Market Drivers -The growing adoption of personalized medicine is expected to propel the growth of the peptide and oligonucleotide CDMO markets going forward. Personalized medicine is an approach to healthcare that tailors medical decisions and treatments to individual characteristics, such as genetics, environment, and lifestyle. The growing adoption of personalized medicine is due to several factors such as advancements in genomic technologies, increased understanding of disease mechanisms at the molecular level, and the demand for more effective and targeted treatment options tailored to individual patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a crucial role in personalized medicine by producing customized therapeutic peptides and oligonucleotides tailored to individual patient needs. For instance, in February 2024, according to the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the peptide and oligonucleotide CDMO market.
Market Trends - Major companies operating in the peptide and oligonucleotide CDMO market are focusing on developing strategic partnerships to enhance their service offerings, expand their technological capabilities, and increase their market reach. Peptide development and production partnerships refer to collaborative agreements between two organizations focused on developing and manufacturing peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), partnered with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This partnership aims to utilize PolyPeptide's cGMP manufacturing capacities and market access, along with Numaferm's expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is focused on jointly exploring the development of suitable peptide candidates with the goal of more sustainable production of peptide-based APIs.
The peptide and oligonucleotide cdmo market covered in this report is segmented –
1) By Product: Peptides, Oligonucleotides 2) By Service Type: Contract Development, Contract Manufacturing, 3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications 4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users
Get an inside scoop of the peptide and oligonucleotide cdmo market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp
Regional Insights - North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies - Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
Table of Contents 1. Executive Summary 2. Peptide And Oligonucleotide CDMO Market Report Structure 3. Peptide And Oligonucleotide CDMO Market Trends And Strategies 4. Peptide And Oligonucleotide CDMO Market – Macro Economic Scenario 5. Peptide And Oligonucleotide CDMO Market Size And Growth ….. 27. Peptide And Oligonucleotide CDMO Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix
Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: [email protected]
Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
0 notes
Text
Oligonucleotide Synthesis Market Future Growth, Scope, Price, and Forecast 2032
Oligonucleotide synthesis has emerged as a crucial component in modern biotechnology, enabling precise manipulation of genetic material for applications ranging from medical diagnostics to therapeutics. These short DNA or RNA molecules, commonly synthesized in laboratories, are instrumental in gene editing, polymerase chain reactions (PCR), molecular cloning, and various other research methods. With advances in synthetic biology, oligonucleotides have become fundamental tools for developing targeted therapies, especially for genetic disorders and cancer treatments. The field has seen remarkable growth as researchers and clinicians leverage these synthesized sequences to enhance accuracy and efficiency in gene-targeting techniques.
The synthesis of oligonucleotides requires highly specialized equipment and meticulous methodologies to ensure the precision of each nucleotide sequence. Leading techniques, such as solid-phase synthesis, phosphoramidite chemistry, and enzymatic synthesis, have contributed to achieving high-fidelity results, ensuring the effectiveness of synthesized oligonucleotides in clinical and research applications. As demand continues to grow for gene-based therapies, diagnostics, and advanced research applications, the market for oligonucleotide synthesis is projected to witness significant expansion in the coming years.
The Oligonucleotide Synthesis Market size was estimated at USD 3.67 billion in 2023 and is expected to reach USD 11.21 billion by 2032 at a CAGR of 13.22% during the forecast period of 2024-2032.
Future Growth
The future growth of the oligonucleotide synthesis market is anticipated to be driven by the increasing interest in gene-based therapies and personalized medicine. Advances in genomic research are revealing new pathways and genetic markers that can be targeted with precision therapies, propelling the demand for custom-synthesized oligonucleotides. Additionally, expanding applications in gene silencing, antisense oligonucleotides, and CRISPR technology are catalyzing a rise in demand for oligonucleotide synthesis as a tool for genetic intervention and cellular engineering.
Global investments in biotechnology research and development are further strengthening the market outlook. Governments and private institutions are increasingly funding initiatives aimed at discovering new genetic therapies and diagnostic tools, fueling the demand for oligonucleotide synthesis services. The field is also expected to benefit from innovations in synthesis processes, such as automation and miniaturization, which improve efficiency, reduce costs, and enable high-throughput applications in large-scale research studies and clinical applications.
Drivers
The rising prevalence of genetic disorders and chronic diseases is a major driver of the oligonucleotide synthesis market. As gene therapy and molecular diagnostics gain traction in healthcare, oligonucleotide synthesis has become an essential process in developing effective treatments and accurate diagnostic tests. Additionally, the ongoing evolution of biotechnology, characterized by advancements in genome editing tools such as CRISPR-Cas9, continues to drive demand for oligonucleotide synthesis. Researchers rely on synthesized oligonucleotides to design CRISPR guides, primers, and probes, highlighting their value in groundbreaking genetic interventions.
Another significant driver is the growth in pharmaceutical and biotechnological research aimed at creating personalized treatments tailored to an individual’s genetic makeup. As precision medicine gains momentum, the role of synthesized oligonucleotides becomes increasingly central in designing therapies that specifically target the genetic origins of diseases. The demand for high-throughput synthesis is also bolstered by academic and research institutions focusing on genomics, proteomics, and metabolomics, further stimulating the market’s expansion.
Key Takeaways
The oligonucleotide synthesis market is crucial to advancements in biotechnology, particularly in gene-based therapies and molecular diagnostics.
Future growth is expected to be driven by the rise in personalized medicine, genomic research, and innovative genome editing tools.
Major companies such as Integrated DNA Technologies and Thermo Fisher Scientific are pivotal players, investing in advanced synthesis techniques.
The demand is propelled by the rising incidence of genetic disorders and the need for precision medicine solutions.
Technological advancements in synthesis processes, including automation and miniaturization, are set to optimize production efficiency and accuracy.
Get a Free Sample Copy of the Report: https://www.snsinsider.com/sample-request/3722
Conclusion
In conclusion, oligonucleotide synthesis stands at the forefront of biotechnology, empowering researchers, clinicians, and pharmaceutical developers to innovate with precision and specificity. The market is poised for substantial growth, fueled by expanding applications in gene-based research and treatment approaches. As the demand for personalized medicine and targeted therapies rises, synthesized oligonucleotides are expected to play an increasingly important role in diagnosing and treating complex genetic diseases. With continued investment in technological advancements, the future of oligonucleotide synthesis holds promising potential for furthering scientific understanding and improving patient outcomes in healthcare.
0 notes
Text
New Trends of Oligonucleotide Synthesis Market with Industry Analysis by 2024 – 2030
Oligonucleotide Synthesis Industry Overview
The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030.
The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.
Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market
Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.
The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.
The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.
Browse through Grand View Research's Biotechnology Industry Research Reports.
The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030.
The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030.
Key Companies & Market Share Insights
Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.
Key Oligonucleotide Synthesis Companies:
· Thermo Fisher Scientific, Inc.
· Merck KGaA
· Danaher Corporation
· Dharmacon Inc.
· Agilent Technologies
· Bio-synthesis
· Kaneka Eurogentec S.A
· LGC Biosearch Technologies
· Biolegio
· Twist Bioscience
Recent Developments
In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.
In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.
In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.
In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.
In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.
In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.
Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.
0 notes
Text
Active Pharmaceutical Ingredients Market: Key Companies and Emerging Trends 2024-2030
The global active pharmaceutical ingredients market size was estimated at USD 237.47 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.75% from 2024 to 2030.
Advancements in Active Pharmaceutical Ingredient (API) manufacturing, growth of the biopharmaceutical sector, and an increase in geriatric population are among the key drivers of API market. An increase in prevalence of chronic diseases, such as cardiovascular diseases and cancer, is anticipated to boost market growth.
Global geriatric population is increasing. According to UN, in 2022, people aged 65 and above accounted for 771 million of the population, and the number is anticipated to reach 994 million by 2030 to 1.6 billion by 2050. The number of elderly people is showing fastest growth in Africa, with a threefold increase estimated in people aged 60 and above, followed by Latin America, reaching 18.8 billion by 2050. Aging is considered the greatest risk factor for development of diseases, including cardiovascular and neurological diseases. Thus, rapidly growing global geriatric population is resulting to be a high-impact-rendering driver for API market.
Gather more insights about the market drivers, restrains and growth of the Active Pharmaceutical Ingredients Market
Increasing prevalence of infectious diseases and hospital-acquired infections is driving market growth. In addition, growing incidence of cardiovascular, genetic, and neurologic disorders is anticipated to act as a high-impact-rendering driver for market growth. Cardiovascular Diseases (CVDs) are the most prevalent causes of death globally. According to WHO, cardiovascular diseases cause death of 17.9 million people per day and are expected to cause approximately 25 million deaths by 2030. Increasing epidemiology of lifestyle, aided with rising number of smokers globally, growing incidence of obesity, and increasing dietary irregularities, are factors likely responsible to propel market growth. A recent report by the United Nations (UN) in May 2023 suggests that there has been a 75% increase in the number of girls and 61% in the number of boys with obesity in Europe.
Outsourcing of APIs has become profitable over in-house production. However, this trend took a different turn during the COVID-19 pandemic. Companies are looking to diversify their API suppliers and manufacturers to different locations instead of outsourcing it to just one manufacturer. In addition, risk mitigation is done using dual sourcing to ensure a continuous supply. Hence, key companies aim to capitalize on this ongoing outsourcing trend with new acquisitions. For instance, in August 2023, EUROAPI announced its deal to acquire BianoGMP to enhance its CDMO expertise in oligonucleotide manufacturing, which is a high-growth industry. This further demonstrates the company’s plans for vertical integration.
Browse through Grand View Research's Pharmaceuticals Industry Research Reports.
• The global antipsychotic drugs market size was valued at USD 16.88 billion in 2023 and is projected to grow at a CAGR of 6.1% from 2024 to 2030.
• The global drug and gene delivery devices market size was valued at USD 670.0 million in 2023 and is projected to grow at a CAGR of 9.0% from 2024 to 2030.
Active Pharmaceutical Ingredients Market Report Segmentation
Grand View Research has segmented the global active pharmaceutical ingredients market report based on type of synthesis, type of manufacturer, type, application, type of drug, and region:
Type of Synthesis Outlook (Revenue, USD Billion, 2018 - 2030)
• Biotech
o Biotech APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
o Generic APIs
o Innovative APIs
o Biotech APIs Market, By Product (Revenue, USD Billion, 2018 - 2030)
o Monoclonal Antibodies
o Hormones
o Cytokines
o Recombinant Proteins
o Therapeutic Enzymes
o Vaccines
o Blood Factors
• Synthetic
o Synthetic APIs Market, By Type (Revenue, USD Billion, 2018 - 2030)
o Generic APIs
o Innovative APIs
Type of Manufacturer Outlook (Revenue, USD Billion, 2018 - 2030)
• Captive APIs
• Merchant APIs
Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Generic APIs
• Innovative APIs
Application Outlook (Revenue, USD Billion, 2018 - 2030)
• Cardiovascular Diseases
• Oncology
• CNS and Neurology
• Orthopedic
• Endocrinology
• Pulmonology
• Gastroenterology
• Nephrology
• Ophthalmology
• Others
Key Companies & Market Share Insights
Some of the leading players operating in the active pharmaceutical ingredients market include AbbVie, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., and Eli Lilly and Company. Key players are using existing customer bases in the region to prioritize maintaining high-quality standards and gain high market size access. This marketing strategy is useful for brands that have already built trust in the market. These players are heavily investing in advanced technology and infrastructure, allowing them to efficiently process & analyze a large volume of samples. Moreover, companies undertake various strategic initiatives with other companies and distributors to strengthen their market presence.
Evonik, CARBOGEN AMCIS, and Pharmazell, are some of the emerging market participants in the ophthalmic drugs market. These companies focus on achieving funding support from government bodies and healthcare organizations aided with novel product launches to capitalize on untapped avenues.
Key Active Pharmaceutical Ingredients Companies:
• Dr. Reddy’s Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• AbbVie Inc.
• Aurobindo Pharma
• Sandoz International GmbH (Novartis AG)
• Viatris Inc.
• Fresenius Kabi AG
• STADA Arzneimittel AG
Recent Developments
• In August 2023, EUROAPI announced its deal to acquire BianoGMP to enhance its CDMO expertise in oligonucleotide manufacturing, which is a high-growth industry.
• In July 2023, Teva Pharmaceutical Industries Ltd. designed a new strategy for development with potential sale of its API unit on the table. The API manufacturing facility is worth USD 2 billion.
• In June 2023, Lonza acquired Synaffix to improve its ADC services portfolio.
• In April 2023, Eli Lilly announced an investment of USD 1.6 billion in the U.S.-based LEAP Innovation Park. This brings the total investment to USD 3.7 billion to manufacture complex APIs for products such as genetic medicine.
• In February 2023, Lonza completed the manufacturing of its facility in Switzerland. The company enhanced its capacity for its High Potent Active Pharmaceutical Ingredient (HPAPI) manufacturing facility.
• In January 2023, Sterling Pharma Solutions acquired an API manufacturing facility from Novartis in Ringaskiddy, Ireland.
Order a free sample PDF of the Active Pharmaceutical Ingredients Market Intelligence Study, published by Grand View Research.
#Active Pharmaceutical Ingredients Market#Active Pharmaceutical Ingredients Industry#Active Pharmaceutical Ingredients Market size#Active Pharmaceutical Ingredients Market share
0 notes
Text
https://www.scoop.it/topic/healthcare-by-soumya-fw/p/4151019085/2024/02/16/oligonucleotide-synthesis-market-size-analysis-and-forecast-2031
Oligonucleotide Synthesis Market Size, Analysis and Forecast 2031
#Oligonucleotide Synthesis Market#Oligonucleotide Synthesis Market Scope#Oligonucleotide Synthesis Market Size
0 notes
Text
0 notes
Text
A full-size, high-density RNA microchip is about the size of a fingernail and can contain up to 780,000 unique RNA sequences, each covering an area of about 14 x 14 μm².
Tadika Kekić
The next generation of RNA chips
Research team achieves breakthrough: chemical synthesis of high-density RNA microarrays now faster and more efficient
An international research team led by the University of Vienna has succeeded in developing a new version of RNA building blocks with higher chemical reactivity and light sensitivity. This can significantly reduce the production time of RNA chips used in biotechnological and medical research. The chemical production of these chips is now twice as fast and seven times more efficient. The results of the research work were recently published in the renowned journal Science Advances.
The emergence and market approval of RNA-based medical products, such as mRNA vaccines during the COVID-19 pandemic, has also brought the RNA molecule into the public eye. RNA (ribonucleic acid) is an information-carrying polymer - a chemical compound made up of similar subunits - but with a far greater structural and functional diversity than DNA. About 40 years ago, a method for the chemical synthesis of DNA and RNA was developed in which any sequence can be assembled from DNA or RNA building blocks using phosphoramidite chemistry. A nucleic acid chain is built up step by step using these special chemical building blocks (phosphoramidites). Each building block carries chemical "protective groups" that prevent unwanted reactions and ensure the formation of a natural link in the nucleic acid chain.
Mastering challenges
This chemical method is also used in the production of microchips ("microarrays"), where millions of unique sequences can be synthesized and analyzed simultaneously on a solid surface the size of a fingernail. While DNA microarrays are already widely used, adapting the technology to RNA microarrays has proven difficult due to the lower stability of RNA.
Back in 2018, the University of Vienna demonstrated how high-density RNA chips can be produced using photolithography: By precisely positioning a beam of light, areas on the surface can be prepared for the attachment of the next building block through a photochemical reaction. Although this first report was a world first and remains unchallenged to this day, the method suffered from its long production time, low yield and low stability. Now this approach has been massively improved.
Development of a new generation of RNA building blocks
A team from the Institute of Inorganic Chemistry at the University of Vienna, in collaboration with the Max Mousseron Institute for Biomolecules at the University of Montpellier (France), has now developed a new version of RNA building blocks with higher chemical reactivity and light sensitivity. This advance significantly shortens the production time of RNA chips and makes synthesis twice as fast and seven times more efficient. The innovative RNA chips are capable of screening millions of RNA candidates for valuable sequences for a wide range of applications.
"The production of RNA microarrays with functional RNA molecules was simply out of reach with our previous setup. With the improved method using the propionyloxymethyl (PrOM) group as a protecting group, it is now possible," says Jory Lietard, Assistant Professor at the Institute of Inorganic Chemistry.
As a direct application of these improved RNA chips, the publication includes a study of RNA aptamers, small oligonucleotides that bind specifically to a target molecule. Two "glowing" aptamers were selected that produce fluorescence when binding to a dye, and thousands of variants of these aptamers were synthesized on the chip. A single binding experiment is sufficient to obtain data on all variants simultaneously, paving the way for the identification of improved aptamers with better diagnostic properties.
"High-quality RNA chips could be particularly valuable in the rapidly growing field of non-invasive molecular diagnostics. New and improved RNA aptamers are desperately sought, e.g. those that can track hormone levels in real time or monitor other biological markers directly from sweat or saliva," says Tadija Kekić, PhD student in Jory Lietard's group.
This work was financially supported by a joint grant from the Agence Nationale pour la Recherche/Austrian Science Fund (FWF Individual Project International I4923).
Original publication:
Publication in "Science Advances" T. Kekić, N. Milisavljević, J. Troussier, A. Tahir, F. Debart and J. Lietard: Accelerated, high quality photolithographic synthesis of RNA microarrays in situ https://www.science.org/doi/10.1126/sciadv.ado6762 doi: 10.1126/sciadv.ado6762
1 note
·
View note